Why Shares of Eli Lilly Soared This Week
Shares in Eli Lilly (NYSE: LLY) had risen 13.2% in the week to Friday morning. The move comes at a time when peer Pfizer announced a deal with the Trump administration that gave that pharmaceutical company three years of grace from tariffs imposed on drugs it manufactures abroad and imports to the U.S.. The deal, which is conditional on Pfizer investing in manufacturing in the U.S., raises hopes that Eli Lilly will also come to a similar agreement with the government.Eli Lilly is in a good position for a couple of reasons. First, it's already investing heavily in the U.S. with a $5 billion manufacturing facility planned in Virginia, as well as a $6.5 billion manufacturing facility planned in Texas. Second, Eli Lilly has already announced an intent to rebalance the costs of its research by increasing the prices paid by governments and healthcare bodies "in other developed markets like Europe in order to make them lower in the U.S." Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Übrigens: Eli Lilly und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Eli Lilly
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Eli Lilly
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: MotleyFool
Nachrichten zu Eli Lilly
Analysen zu Eli Lilly
Datum | Rating | Analyst | |
---|---|---|---|
20.12.2024 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.2024 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.2024 | Eli Lilly and Buy | Jefferies & Company Inc. | |
05.10.2018 | Eli Lilly and Outperform | BMO Capital Markets | |
25.07.2018 | Eli Lilly and Neutral | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
20.12.2024 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.2024 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.2024 | Eli Lilly and Buy | Jefferies & Company Inc. | |
05.10.2018 | Eli Lilly and Outperform | BMO Capital Markets | |
08.06.2018 | Eli Lilly and Overweight | Cantor Fitzgerald |
Datum | Rating | Analyst | |
---|---|---|---|
25.07.2018 | Eli Lilly and Neutral | Goldman Sachs Group Inc. | |
27.04.2017 | Eli Lilly and Hold | Argus Research Company | |
20.03.2017 | Eli Lilly and Neutral | UBS AG | |
22.07.2015 | Eli Lilly and Equal Weight | Barclays Capital | |
08.01.2015 | Eli Lilly and Hold | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
21.04.2017 | Eli Lilly and Underperform | BMO Capital Markets | |
15.10.2012 | Eli Lilly and underperform | Jefferies & Company Inc. | |
30.06.2010 | Eli Lilly Ersteinschätzung | Soleil Securities Group, Inc. | |
14.12.2009 | Eli Lilly sell | Goldman Sachs Group Inc. | |
02.12.2009 | Eli Lilly sell | Goldman Sachs Group Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Eli Lilly nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen